Pancreatic angiotensin-converting enzyme 2 improves glycemia in angiotensin II-infused mice

American Journal of Physiology - Endocrinology and Metabolism

Volumn 304, Issue 8, 2013, Pages

  Chhabra, Kavaljit H ^a   Xia, Huijing ^a   Pedersen, Kim Brint ^a   Speth, Robert C ^b,c   Lazartigues, Eric ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cell dysfunction; Angiotensin II; Angiotensin II type; Angiotensin converting enzyme 2; Diabetes mellitus; Oxidative stress; Receptor; Type

Indexed keywords

ADENOVIRUS VECTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ENHANCED GREEN FLUORESCENT PROTEIN; INSULIN; RECOMBINANT ANGIOTENSIN CONVERTING ENZYME 2; RECOMBINANT PROTEIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG INFUSION; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VIRAL GENE DELIVERY SYSTEM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOVIRIDAE; ANGIOTENSIN II; ANIMALS; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; GENETIC THERAPY; HUMANS; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; VASOCONSTRICTOR AGENTS;

EID: 84878498307     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00490.2012     Document Type: Article

References (48)

1. Alenina N, Xu P, Rentzsch B, Patkin EL, Bader M. Genetically altered animal models for Mas and angiotensin-(1-7). Exp Physiol 93: 528-537, 2008.
2. Benicky J, Hafko R, Sanchez-Lemus E, Aguilera G, Saavedra J. Six commercially available angiotensin II AT1 receptor antibodies are nonspecific. Cell Mol Neurobiol 32: 1353-1365, 2012.
3. Bindom SM, Hans CP, Xia H, Boulares AH, Lazartigues E. Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes 59: 2540-2548, 2010.
4. Bindom SM, Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol Cell Endocrinol 302: 193-202, 2009.
5. Butz GM, Davisson RL. Long-term telemetric measurement of cardiovascular parameters in awake mice: a physiological genomics tool. Physiol Genomics 5: 89-97, 2001.
6. Carlsson PO, Andersson A, Jansson L. Pancreatic islet blood flow in normal and obese-hyperglycemic (ob/ob) mice. Am J Physiol Endocrinol Metab 271: E990-E995, 1996.
7. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41: 127-133, 1998.
8. Cha DR, Zhang X, Zhang Y, Wu J, Su D, Han JY, Fang X, Yu B, Breyer MD, Guan Y. Peroxisome proliferator activated receptor alpha/ gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 56: 2036-2045, 2007.
9. Chappell M, Millsted A, Diz D, Brosnihan K, Ferrario CM. Evidence for an intrinsic angiotensin system in the canine pancreas. J hypertens 9: 751-759, 1991.
10. Chhabra K, Pedersen KB, Lazartigues E. Renin-angiotensin system and diabetes. In: Beta Cells: Functions, Pathology and Research, edited by Gallagher SE. Hauppauge, NY: NOVA Publishers, 2011, p. 151-163.
11. Chu KY, Lau T, Carlsson PO, Leung PS. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 55: 367-374, 2006.
12. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1-E9, 2000.
13. Feng Y, Xia H, Cai Y, Halabi CM, Becker LK, Santos RA, Speth RC, Sigmund CD, Lazartigues E. Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ Res 106: 373-382, 2010.
14. Feng Y, Yue X, Xia H, Bindom SM, Hickman PJ, Filipeanu CM, Wu G, Lazartigues E. Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ Res 102: 729-736, 2008.
15. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100: 2158-2169, 1997.
16. Folli F, Saad MJ, Velloso L, Hansen H, Caradente O, Feener E, Kahn CR. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 107: 133-139, 1999.
17. Giani JF, Mayer MA, Muñoz MC, Silberman EA, Höcht C, Taira CA, Gironacci MM, Turyn D, Dominici FP. Chronic infusion of angiotensin-(1-7) improves insulin resistance and hypertension induced by a highfructose diet in rats. Am J Physiol Endocrinol Metab 296: E262-E271, 2009.
18. Henriksen EJ. Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 293: R974-R980, 2007.
19. Huang Z, Jansson L, Sjöholm A. Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glucose tolerance in female rats. Clin Sci (Lond) 112: 69-76, 2007.
20. Ikeda N, Inoguchi T, Sonoda N, Fujii M, Takei R, Hirata E, Yokomizo H, Zheng J, Maeda Y, Kobayashi K, Takayanagi R. Biliverdin protects against the deterioration of glucose tolerance in db/db mice. Diabetologia 54: 2183-2191, 2011.
21. Leung KK, Leung PS. Effects of hyperglycemia on the angiotensin II receptor type 1 expression and insulin secretion in an INS-1E pancreatic beta-cell line. JOP 9: 290-299, 2008.
22. Leung PS, Chan HC, Fu LX, Wong PY. Localization of angiotensin II receptor subtypes AT1 and AT2 in the pancreas of rodents. J Endocrinol 153: 269-274, 1997.
23. Leung PS, Chan HC, Wong PY. Immunohistochemical localization of angiotensin II in the mouse pancreas. Histochem J 30: 21-25, 1998.
24. Leung PS, Chan WP, Wong TP, Sernia C. Expression and localization of the renin-angiotensin system in the rat pancreas. J Endocrinol 160: 13-19, 1999.
25. Machado LJ, Marubayashi U, Reis AM, Coimbra CC. The hyperglycemia induced by angiotensin II in rats is mediated by AT1 receptors. Braz J Med Biol Res 31: 1349-1352, 1998.
26. Meigs JB, Larson MG, Fox CS, Keaney JF Jr, Vasan RS, Benjamin EJ. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care 30: 2529-2535, 2007.
27. Mitsuishi M, Miyashita K, Muraki A, Itoh H. Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic control. Diabetes 58: 710-717, 2009.
28. Niu MJ, Yang JK, Lin SS, Ji XJ, Guo LM. Loss of angiotensinconverting enzyme 2 leads to impaired glucose homeostasis in mice. Endocrine 34: 56-61, 2008.
29. Pedersen KB, Sriramula S, Chhabra KH, Xia H, Lazartigues E. Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays. Am J Physiol Regul Integr Comp Physiol 301: R1293-R1299, 2011.
30. Raizada MK, Ferreira AJ. ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 50: 112-119, 2007.
31. Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int 74: 1610-1616, 2008.
32. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 279: 42351-42354, 2004.
33. Saiki A, Ohira M, Endo K, Koide N, Oyama T, Murano T, Watanabe H, Miyashita Y, Shirai K. Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus. Metabolism 58: 708-713, 2009.
34. Santos SH, Braga JF, Mario EG, Pôrto LC, Rodrigues-Machado Mda G, Murari A, Botion LM, Alenina N, Bader M, Santos RA. Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). Arterioscler Thromb Vasc Biol 30: 953-961, 2010.
35. Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, Okumura M, Cui TX, Horiuchi M. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43: 1003-1010, 2004.
36. Speth RC. Sarcosine1, glycine8 angiotensin II is an AT1 angiotensin II receptor subtype selective antagonist. Regul Pept 115: 203-209, 2003.
37. Sriramula S, Cardinale JP, Lazartigues E, Francis J. ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension. Cardiovasc Res 92: 401-408, 2011.
38. Tahmasebi M, Puddefoot JR, Inwang ER, Vinson GP. The tissue reninangiotensin system in human pancreas. J Endocrinol 161: 317-322, 1999.
39. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41: 392-397, 2003.
40. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the reninangiotensin system in the ZDF rat. Diabetes 53: 989-997, 2004.
41. Tocci G, Paneni F, Palano F, Sciarretta S, Ferrucci A, Kurtz T, Mancia G, Volpe M. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebocontrolled clinical trials. Am J Hypertens 24: 582-590, 2011.
42. Treml B, Neu N, Kleinsasser A, Gritsch C, Finsterwalder T, Geiger R, Schuster M, Janzek E, Loibner H, Penninger J, Loeckinger A. Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. Crit Care Med 38: 596-601, 2010.
43. Xia H, Feng Y, Obr TD, Hickman PJ, Lazartigues E. Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice. Hypertension 53: 210-216, 2009.
44. Xia H, Suda S, Bindom S, Feng Y, Gurley SB, Seth D, Navar LG, Lazartigues E. ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. PLoS One 6: e22682, 2011.
45. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 17: 3067-3075, 2006.
46. Zhong JC, Yu XY, Lin QX, Li XH, Huang XZ, Xiao DZ, Lin SG. Enhanced angiotensin converting enzyme 2 regulates the insulin/Akt signalling pathway by blockade of macrophage migration inhibitory factor expression. Br J Pharmacol 153: 66-74, 2008.
47. Zhou L, Zhang R, Yao W, Wang J, Qian A, Qiao M, Zhang Y, Yuan Y. Decreased expression of angiotensin-converting enzyme 2 in pancreatic ductal adenocarcinoma is associated with tumor progression. Tohoku J Exp Med 217: 123-131, 2009.
48. Zmuda EJ, Powell CA, Hai T. A method for murine islet isolation and subcapsular kidney transplantation. J Vis Exp: 2096, 2011.